New Bipolar Disorder Study Shows that a Ketogenic Diet Leads to Mental and Physical Health Benefits
Baszucki Group today announced a new pilot study on a ketogenic diet in bipolar disorder. “For the first time in years, I felt like my brain was finally running on the right fuel,” said one of the study participants. Published today in BJPsych Open, the study is the first to use neuroimaging to demonstrate that a ketogenic diet may improve brain metabolism in individuals with a bipolar disorder diagnosis. With over 100 years of evidence of efficacy in epilepsy, a ketogenic diet is now being studied around the world for a variety of psychiatric and neurological conditions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211683582/en/
The first-of-its-kind European study, supported by Baszucki Group, used advanced brain imaging techniques, including magnetic resonance spectroscopy (MRS), to measure changes in brain metabolism. The imaging revealed reductions in excitatory neurotransmitters typically elevated in bipolar disorder, suggesting a potential mechanism behind a ketogenic diet's effectiveness. The study also showed that ketone levels correlated with symptom improvement in a subset of individuals who reported daily ratings. This pilot trial points to an important new direction for research and offers hope for innovative treatment options for individuals living with this serious mental illness.
Co-led by University of Edinburgh scientists Iain Campbell, PhD, a Baszucki Metabolic Psychiatry Research Fellow, Daniel Smith, MD, FRCPsych, Chair of Psychiatry, and Harry Campbell, MD, FRSE, FMedSci, the research team enrolled 27 participants with bipolar disorder into a 6-8 week pilot trial of a ketogenic diet. Twenty participants completed the study, demonstrating that the intervention was safe and tolerable in this population. Most reached and maintained ketosis, with 91% of readings positive for blood ketones. Among participants who provided reliable daily ketone and mental health data assessments, increased ketone level was correlated with improvements in mood, energy, impulsivity, and anxiety, with some describing the intervention as life-changing.
“A ketogenic diet gave me a lifeline, restoring my energy and sense of hope,” said a study participant. “I felt like I was finally healing my mind, not just managing my bipolar symptoms. It opened me up to new possibilities and a brighter future.”
“Using a ketogenic diet is like giving my mind a warm bath,” said another participant. “The edginess is gone. I feel calmer, clearer, and my brain is working again.”
Markers of metabolic function also improved. Nineteen of 20 participants lost an average of 9.3 pounds (4.2kg) and saw improvements in body mass index (BMI) and blood pressure. These findings suggest that a ketogenic diet may help mitigate common metabolic health risks associated with bipolar disorder and its pharmacological treatments, which can lead to shortened life spans.
“We observed markers of reduced excitotoxicity in two key brain areas: the anterior cingulate cortex and posterior cingulate cortex—both implicated in bipolar disorder. We also observed effects on a marker which has been associated with Lithium and insulin signaling in the posterior cingulate cortex ” said Dr. Iain Campbell, who also lives with the disorder and follows a ketogenic diet to alleviate his symptoms. “These results add to a small but growing body of evidence suggesting that a ketogenic diet may be an effective adjunctive metabolic intervention for bipolar disorder. There is an urgent need for larger replication studies and carefully designed randomized clinical trials to build on these findings."
These changes align with the metabolic overdrive hypothesis, a theory Drs. Campbell have proposed, which posits that energy dysregulation is central to the mechanism of bipolar disorder and that addressing this dysregulation may be key to the success of ketogenic diet therapy.
A New Frontier in Mental Health
This pilot study paved the way for a broader initiative at the University of Edinburgh, made possible by a competitive research grant from the UKRI Medical Research Council that established the first European Metabolic Psychiatry Hub. The hub, to which Baszucki Group also contributed funding, is a collaboration of over 100 scientists dedicated to accelerating research into the connections between metabolism and mental health. Its focus is to explore the potential of ketogenic therapy and other metabolic interventions for treating severe mental illnesses.
This study is the second recently published pilot trial to demonstrate the safety and potential efficacy of ketogenic therapy in improving both metabolic and mental health markers in serious mental illness. The first trial, also funded by Baszucki Group, was conducted at Stanford University and also suggested that systemic metabolic changes from a ketogenic diet may help stabilize the brain in serious mental illness.
“This trial is another important step forward in establishing ketogenic therapy as a standard treatment for serious mental illness,” said Jan Ellison Baszucki, co-founder and President of Baszucki Group. “We’re proud to have supported this research and remain hopeful that ongoing studies will continue to advance our understanding of the metabolic intervention that saved our son’s life.”
As awareness grows about the deep connection between metabolic function and brain health, this study advances the global scientific movement toward neurometabolic approaches to understanding and treating mental illness.
About Baszucki Group
Launched in 2021 by Roblox founder and Chief Executive Officer David Baszucki and best-selling author Jan Ellison Baszucki, Baszucki Group leverages private giving, impact investing, advocacy, storytelling and community building to drive foundational change. A primary objective of Baszucki Group is to transform mental health outcomes by supporting initiatives at the intersection of metabolism, psychiatry, and neuroscience. To learn more about metabolic approaches to mental disorders, including ketogenic therapy, visit Metabolic Mind, a nonprofit initiative of Baszucki Group.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250211683582/en/
Contacts
Colby Zintl colby@baszuckigroup.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Novotech Wins Citeline CRO Partnership of the Year Award for Strategic Collaboration with Tune Therapeutics13.5.2025 15:05:00 EEST | Press release
Novotech a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is proud to announce it has been awarded the Citeline CRO Partnership of the Year Award in recognition of its collaboration with Tune Therapeutics, a pioneering epigenetic editing company. This honor celebrates the teams’ partnership and sets a benchmark for CRO–biotech partnerships. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513574699/en/ Novotech is proud to announce it has been awarded the Citeline CRO Partnership of the Year Award in recognition of its collaboration with Tune Therapeutics. The CRO Partnership of the Year award honors outstanding collaboration between a CRO and a pharmaceutical or biotech company that has advanced clinical programs through strong alignment and shared goals. Sarah Anderson, Director of Therapeutic Strategy, and Steve Roan, Associate Director of Business Development, acce
KnowBe4 Report Reveals Security Training Reduces Global Phishing Click Rates by 86%13.5.2025 15:00:00 EEST | Press release
KnowBe4, the world-renowned cybersecurity platform that comprehensively addresses human risk management, today launched its “Phishing by Industry Benchmarking Report 2025” which measures an organization’s Phish-prone™ Percentage (PPP) — the percentage of employees likely to fall for social engineering or phishing attacks, indicating the organization’s overall susceptibility to phishing threats. This year’s report found a global average baseline PPP of 33.1%, meaning a third of employees interact with phishing simulations before taking part in best-practice security awareness training (SAT). The data underscores the significant impact of SAT in mitigating risk. The rapid decline in the global PPP following the implementation of training — falling by 40% in just three months and by a total of 86% after 12 months — demonstrates that ongoing, effective training leads to lasting behavior change and a substantial reduction in vulnerability to cybersecurity threats. This highlights the critic
Armis Announces New Global Technology Integration Partners to Bolster Organizations’ Cyber Resilience13.5.2025 15:00:00 EEST | Press release
Armis, the cyber exposure management & security company, today announced that it has added 10 global technology integration partners over the past quarter. These integrations increase the functionality and efficiency of organizations’ existing technology stacks with added benefits from Armis’ platform and solutions. “Relying on siloed security solutions is no longer enough to gain a comprehensive, real-time understanding of an organization’s attack surface,” said Nadir Izrael, CTO and Co-Founder at Armis. “Integrating Armis’ best-in-class platform with other leading vendors’ offerings empowers businesses to consolidate their technology stacks. By driving greater value in their security investments, organizations can ensure their entire attack surface is continuously defended and managed.” New Armis global technology integration partners include AnzenOT, Brinqa, ColorTokens, EasyVista, SaltyCloud, Salvador Tech, SIGA, Spectro Cloud, Stellar Cyber, and Synqly. From compliance to network
Kyriba Unveils Agentic AI TAI to Transform Finance with Security, Compliance & Trust13.5.2025 14:35:00 EEST | Press release
Kyriba, a global leader in liquidity performance, today introduced its agentic AI solution, TAI – a significant advancement in the safe, compliant use of generative AI in finance operations to improve productivity and efficiency amid continued economic uncertainty. Powered by Kyriba's embedded Large Language Model (LLM) and over 20 years of unmatched global liquidity data, TAI simplifies complex workflows, identifies risks with predictive analytics, and enhances data-driven decision-making across treasury, payments, risk management and working capital. Poised to transform finance and treasury operations without relying on third-party LLM integrations, TAI is a key component of Kyriba’s Trusted AI portfolio. This platform-wide approach prioritizes industry-leading data privacy while empowering enterprise leaders to make faster, smarter decisions with human judgement and responsibility at the center. Kyriba’s approach directly addresses the "Trust Gap" – the growing divide between the pr
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference13.5.2025 13:01:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will participate in the RBC Capital Markets Global Healthcare Conference on May 20, 2025, with a fireside chat at 10 a.m. EDT. The live webcast of this event can be accessed from the investors section of the Company’s website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. An archived replay will be available for 1 year following the event. About BeiGene BeiGene, which will change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom